Most of the tumor tissues were positive for PCP4/PEP19 irrespective of hormone receptor status, indicating that PCP4/PEP19 may present an attractive and alternative therapeutic target in breast cancer, especially in hormone-independent breast cancers. Here, NR4A1 is linked to breast carcinoma.